Abstract
With the sequencing of the human genome comes the promise of advances in medical science. For this promise to be fully realized, researchers must have access to information resulting from this landmark endeavor as well as from subsequent research initiatives. However, because genomic sequences are potential sources of profit for the biotechnology and pharmaceutical industries, many private companies seek to limit access to this information. Some argue that this will impede scientific progress and increase the cost of basic research, while others argue that the privatization of genetic information is needed to assure profits and generate the considerable funding necessary to bring therapeutic products to the market. In analyzing the arguments for both sides, we conclude that both private funding and public access to information are important in genetic research. Precedents for compromise are necessary, as is increased dialog between private and public interests in order to ensure continued advancements in genetic science and medicine.
Similar content being viewed by others
Notes
1The HGP, sponsored by the Department of Energy and National Institutes of Health Genome Programs, is the national coordinated effort to characterize all human genetic material by determining the complete sequence of the DNA in the human genome. The HGI is a separate initiative, and is an international research program for the creation of detailed genetic and physical maps for each of the 24 different human chromosomes and the elucidation of the complete DNA sequence of the human genome.
References
Semple CA. Bases and spaces: resources on the web for accessing the draft human genome — II — after publication of the draft. Genome Biol 2001 Jun; 2(6): 1–7
The scramble to patent human genes. Nature Neurosci 1999 Sep; 2: 773
Pearson PL. Genome mapping databases: data acquisition, storage and access. Curr Sci 1991; 1: 119–23
Cook-Deegan RM, McCormack SJ. Intellectual property: patents, secrecy and DNA. Science 2001 Jul; 293(5528): 217
Eisenberg R. Intellectual property issues in genomics. Bioinformations 1996 Aug; 14: 302–7
Knoppers BM, Laberge CM. Ethical guideposts for allelic variation databases. Hum Mutat 2000; 15: 30–5
Goodman L. Unlimited access: limitless success. Genome Res 2001; 11: 637–8
Lyttle J. Issues concerning ethical conduct and genetic mapping raised at Montreal meeting. CMAJ 1997 Feb; 156(3): 411–2
Butler D, Smaglik P. Celera genome licensing terms spark concerns over ‘monopoly’. Nature 2000 Jan; 403: 231
Katzman S. What is patent worthy? Eur Mol Biol Org Rep 2001; 2(2): 88–90
Pennisi E. Academic sequencers challenge Celera in a sprint to the finish. Science 1999 Mar; 283: 1822–3
Butler D. US/UK statement on genome data prompts debate on ‘free access’. Nature 2000 Mar; 404: 324–5
Harris RF. Patenting genes: is it necessary and is it evil? Curr Biol, 2000; 10(5): R174–5
Bonetta L. Raising the bar for genetic patents. Curr Biol 2001; 11(2): R115–6
Celera Discover System Overview [online]. Available from URL: http://www.celera.com/genomics/academic [Accessed 2002 Aug 5]
Williams KM. New draconian restrictions on US patent scope: FESTO. Palmer & Dodge, LLP 2001 [online]. Available from URL: http://www.palmerdodge.com/dspSingleArticle.cfm?.Articleid=352 [Accessed 2002 Aug 5]
Williams KM. Genome success means difficult patent questions. Palmer & Dodge, LLP 2000 [online]. Available from URL: http://www.palmerdodge.com/dspSingleArticle.cfm?.Articleid=175 [Accessed 2002 Aug 5]
Burris JR, Cook-Deegan M, Alberts B. The Human Genome Project after a decade: policy issues. Nature Genet 1998 Dec; 20: 333–5
Ayme S. Bridging the gap between molecular genetics and metabolic medicine: access to genetic information. Eur J Pediatr 2000; 159(S183): 183–5
Skupski MP, Booker M, Farmer A, et al. The genome sequence database: towards an integrated functional genomics resource. Nucleic Acids Res 1998 Nov; 27(1): 35–8
Adler RG. Genome research: fulfilling the public’s expectations for knowledge and commercialization. Science 1992 Aug; 257: 908–14
Gu Z, Hiller L. Single nucleotide polymorphism hunting in cyberspace. Hum Mutat 1998 May; 12: 221–5
Norman F. Genetic information resources: a new field for medical librarians. Health Libr Rev 1999; 16: 15–28
Doll JJ. The patenting of DNA. Science 1998 May; 280: 689–90
Marshall E. The battle over BRCA1 goes to court; BRCA2 may be next. Science 1997 Dec; 278: 1874
Roses, AD. Genetic testing for Alzheimer disease: practical and ethical issues. Arch Neurol 1997 Oct; 54(10): 1226–9
Lytton M. Patent problems in the gene pool. Palmer & Dodge, LLP 1999 [online]. Available from URL: http://www.palmerdodge.com/dspSingleArticle.cfm?.Articleid=114 [Accessed 2002 Aug 5]
Stephens D. Wellcome Trust discourages Celera subscribers. Trends Cell Biol 2001 Jul; 11(7): 284
Rabino I. How human geneticists in US view commercialization of the Human Genome Project. Nature Genet 2001 Sep; 29: 15–6
Caulfield T. The commercialization of human genetics: profits and problems. Mol Med Today 1998 Apr; 4: 148–50
Chadwick R, Berg K. Solidarity and equity: new ethical frameworks for genetic databases. Nat Rev 2001 Apr; 2: 318–21
Acknowledgements
The authors have no conflicts of interest that are directly relevant to the content of this manuscript.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Marks, A.D., Steinberg, K.K. The Ethics of Access to Online Genetic Databases. Am J Pharmacogenomics 2, 207–212 (2002). https://doi.org/10.2165/00129785-200202030-00006
Published:
Issue Date:
DOI: https://doi.org/10.2165/00129785-200202030-00006